Market closed · Next open: Monday 9:30 AM ET
Last update: Nov 20, 2026, 6:14 PM ET
ResMed Inc.
$235.63▼ 0.53% today
Market Closed

Why ResMed Inc. (RMD) stock moved

No significant move on Nov 20, 2026 (−0.5%, close-to-close). Latest notable session: Oct 30, 2026.

Latest session▼ 9.1% · Oct 30, 2026 close

Why ResMed Inc. (RMD) fell 9.1% on October 30, 2026

ResMed Inc. (RMD) fell 9.1% on October 30, 2026, closing at $229.94 versus $252.83 the prior session (close-to-close, from daily closes). The decline stems from management's decision to reiterate rather than raise full-year guidance despite the beat, combined with the permanent discontinuation of its Astral 100 and 150 portable ventilator lines due to a circuit board safety issue—creating an estimated $75M revenue headwind (~130 basis points) for fiscal 2027. Volume is elevated at 2.18x the time-adjusted average, signaling intensified selling pressure. Source: zacks.com.

Updated
Prior close
$252.83
Oct 30, 2026 close
$229.94
Change (close-to-close)
−$22.89
−9.05%
As first detected · Oct 30, 2026, 10:12 AM ET

ResMed beat Q1 fiscal 2027 earnings (non-GAAP EPS $2.91 vs. $2.67–$2.68 expected; revenue $1.41B) and gross margin improved, per Zacks, yet the stock fell 8.26% to $231.95. The decline stems from management's decision to reiterate rather than raise full-year guidance despite the beat, combined with the permanent discontinuation of its Astral 100 and 150 portable ventilator lines due to a circuit board safety issue—creating an estimated $75M revenue headwind (~130 basis points) for fiscal 2027. Volume is elevated at 2.18x the time-adjusted average, signaling intensified selling pressure.

What to watch next: Management commentary on the ventilator discontinuation's operational and supply-chain impact during the next earnings call or investor update; Q2 fiscal 2027 results (scheduled 2027-01-28) and whether consensus EPS estimate of $3.03 holds against the revised guidance envelope.

Source: zacks.com · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved RMD

  1. +2.8%Driven by anticipation ahead of its October 29 fiscal Q1 earnings report (consensus EPS $2.69, revenue ~$1.39B) and positive momentum from the recent U.S. launch of its AirTouch™ F40 full-face fabric CPAP mask.
  2. +2.9%As investors positioned ahead of the company's Q1 fiscal 2027 earnings release scheduled for October 29, 2026.
  3. −3.6%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.

ResMed Inc. (RMD) shares fell 0.5% to $235.63 as of November 22, 2026, a slight decline from the prior close of $236.88. BestStocks flagged the session as a major change for RMD. The move is tied to company news. Below, we break down what changed for RMD, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Company News

Law firm Levi & Korsinsky initiated investigation into ResMed officers and directors for possible fiduciary duty breaches. Litigation risk could result in executive changes, governance reforms, or shareholder recoveries affecting RMD's leadership and operations.

This summary describes the catalyst and move as first detected on Nov 10, 2026, 10:14 AM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsWeak confidence
Rel. volume
1.0×
Normal
Vs peers
—
No comparable peers
Market cap
$33.1B
New York Stock Exchange
Analyst target
$247
+4.8% vs price
Price chart
Oct 22 – Nov 20
NVFFFE$227$240$254Oct 22Oct 29Nov 6Nov 13Nov 20
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for ResMed Inc. investors

For ResMed Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Negative session, down 0.5%; RMD moved -6.33% from $219.75 to $205.84 on 2026-07-08. Wall Street's consensus price target sits at $246.89, implying +4.8% upside from $235.63. Over the past 90 days analysts logged 1 upgrade and 1 downgrade. BestStocks rates the overall signal quality weak (36/100). With earnings roughly 67 days out, the next report is the most likely near-term test of the move.

RMD price reaction

RMD last traded at $235.63, down $1.25 (-0.53%) from the previous close of $236.88. The session traded on 1.0× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $227.08 and $253.20, and it currently sits about 33% of the way up that band.

Bullish and bearish analyst opinions on ResMed Inc. (RMD)

The consensus analyst price target on ResMed Inc. (RMD) is $246.89, 4.8% above the recent $235.63. Over the past 90 days analysts logged 1 upgrade, 5 maintains, and 1 downgrade. Here is how the bullish and bearish cases on RMD line up.

The bullish case

  • Wall Street's consensus price target of $246.89 implies +4.8% upside from $235.63.
  • The Street's most bullish target is $300.00 (+27.3%).
  • 1 analyst upgrade in the past 90 days, most recently RBC Capital to Outperform (2026-09-15).
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $213.00 (-9.6%).
  • 1 analyst downgrade in the past 90 days, most recently Canaccord Genuity to Hold (2026-11-02).
  • Negative session, down 0.5%.
  • RMD moved -6.33% from $219.75 to $205.84 on 2026-07-08.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $247+4.8%
↑ 1 upgrades= 5 maintains↓ 1 downgrades
Canaccord Genuity downgraded to Hold · 2026-11-02
SEC filings watch
8-K2026-11-19
Material event — review for impact
high
10-Q2026-10-30
Quarterly financial results
medium
8-K2026-10-29
Material event — review for impact
high
DEF 14A2026-10-01
Annual proxy — exec compensation & governance
low
Peer context
RMD-0.5%

Previous notable changes for RMD

Filings2026-11-19-2.4%
ResMed Inc. (RMD) filed an 8-K on November 19, 2026. The filing content was not disclosed in available sources.
Valuation2026-10-30-9.1%via zacks.com ↗
ResMed beat Q1 fiscal 2027 earnings (non-GAAP EPS $2.91 vs. $2.67–$2.68 expected; revenue $1.41B) and gross margin improved, per Zacks, yet the stock fell 8.26% to $231.95. The decline stems from management's decision to reiterate rather than raise full-year guidance despite the beat, combined with the permanent discontinuation of its Astral 100 and 150 portable ventilator lines due to a circuit board safety issue—creating an estimated $75M revenue headwind (~130 basis points) for fiscal 2027. Volume is elevated at 2.18x the time-adjusted average, signaling intensified selling pressure.
Filings2026-10-30-9.1%
ResMed Inc. (RMD) filed its 10-Q on 2026-10-30.
Filings2026-10-29+1.1%
ResMed Inc. (RMD) filed a new 8-K on October 29, 2026. The filing contents were not detailed in available sources.

In-depth RMD event analyses

Permanent, dated analyses of RMD's most significant sessions.
Upcoming catalysts & outlook
Next earnings
2027-01-28 (est.)
in 67 days
10-Q Filing (est.)
2027-01-29
Medium impact
10-K Annual Report (est.)
2027-08-13
Medium impact
Thesis shift
Bearish Shift
bearish signal
Risk level
Medium
from change events

Frequently asked questions about RMD

Why did ResMed Inc. (RMD) stock move?

ResMed Inc. (RMD) fell 9.1% on October 30, 2026, closing at $229.94 versus $252.83 the prior session (close-to-close, from daily closes). The decline stems from management's decision to reiterate rather than raise full-year guidance despite the beat, combined with the permanent discontinuation of its Astral 100 and 150 portable ventilator lines due to a circuit board safety issue—creating an estimated $75M revenue headwind (~130 basis points) for fiscal 2027. Volume is elevated at 2.18x the time-adjusted average, signaling intensified selling pressure. Source: zacks.com.

How much did RMD stock fall?

RMD lost 0.53% ($1.25) versus the prior close of $236.88, last trading at $235.63 on 1.0× average volume.

When is ResMed Inc.'s next earnings date?

RMD's next earnings report is estimated for 2027-01-28 — about 67 days away.

What is the analyst price target for RMD?

The consensus analyst price target for RMD is $246.89, about 4.8% above the current $235.63. Over the past 90 days, analysts recorded 1 upgrade, 5 maintains, and 1 downgrade.

How BestStocks tracks RMD

This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for RMD, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsCompany news feedsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.